Respiratory Syncytial Virus (RSV)
Respiratory syncytial virus (RSV) increasingly recognized as a significant cause of illness and death in elderly adults. The virus is highly contagious and causes symptoms similar to the common cold, but symptoms may be of increased severity and longer duration. An estimated 11,000 to 17,000 older adults die annually of RSV in the United States, and another 177,500 are hospitalized.
We are seeking volunteers ages 60 and older to participate in an RSV vaccine study. The study will help determine the safety and effectiveness of a single RSV injection compared to a placebo (no active medicine). The participants will be followed over a year by phone and 7 office visits to determine the occurrences of signs or symptoms of a respiratory infection.
Compensation of up to $675 for completed study requirements. In addition, the study participants will be offered a flu vaccine at no cost.
To Qualify you must be:
- 60 years of age or older
- Able to complete study visits & phone access
- Generally healthy with no unstable medical conditions